{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:25Z","timestamp":1792787305655,"version":"4.5.0"},"reference-count":31,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"unspecified","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen Pharmaceutical Companies","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100015311","name":"Novartis Institutes for BioMedical Research","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100015311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Boehringer-Ingelheim Pharma GmbH & Co","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Celgene Corporation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"GlaxoSmithKline plc","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Gilead","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"National Cancer Institute","award":["U24CA224285"],"award-info":[{"award-number":["U24CA224285"]}]},{"name":"National Cancer Institute","award":["U24CA224309"],"award-info":[{"award-number":["U24CA224309"]}]},{"name":"National Cancer Institute","award":["U24CA224316"],"award-info":[{"award-number":["U24CA224316"]}]},{"name":"National Cancer Institute","award":["U24CA224319"],"award-info":[{"award-number":["U24CA224319"]}]},{"name":"AbbVie Inc.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Genentech Inc","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Amgen Inc","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NCI","award":["140D0421D0007"],"award-info":[{"award-number":["140D0421D0007"]}]},{"name":"Foundation for the National Institutes of Health, Inc","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"https:\/\/ror.org\/00k86s890","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,9,14]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with advanced non-small cell lung cancer who progress on immune checkpoint inhibitors (ICIs) face limited options and poor survival. Aglatimagene besadenovec (CAN-2409), a replication-defective adenoviral vector encoding herpes simplex virus-thymidine kinase, plus valacyclovir, has been shown to induce immunogenic cell death and systemic immune activation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this open-label, phase 2a clinical trial, 76 patients were enrolled (intention-to-treat population) and 73 received at least one dose of aglatimagene besadenovec (safety population); 46 patients who received two intratumoral aglatimagene besadenovec injections, completed protocol-defined valacyclovir exposure, and underwent a 12-week imaging comprised the evaluable (per-protocol) population. Endpoints included clinical and immunological outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the 73 patients included in the safety analysis (including patients who did not receive a second injection due to apparent pseudoprogression), median OS was 14.3 months. In the evaluable (per-protocol) population of 46 patients who completed protocol-defined treatment and week-12 imaging, median OS was 24.5 months (95% CI 16.0 to 33.8). Among the 41 evaluable patients in cohort 2, 15 (37%) were alive at \u226524 months and 5 (12%) at \u226540 months. In the 46-patient evaluable population, the objective response rate was 10.9% (5\/46; 95% CI 4.7% to 23.0%) and the disease control rate was 71.7% (33\/46; 95% CI 57.5% to 82.7%). In the 73 patients included in the safety analysis (including patients who did not receive a second injection due to apparent pseudoprogression) median overall survival was 14.3 months. Exploratory biomarkers demonstrated systemic immune reactivation, including cytotoxic T-cell expansion and regression of uninjected lesions, with stronger signals in non-squamous histology. No grade 4 treatment-related adverse events or treatment-related deaths were reported. Most treatment-related adverse events were grade 1\u20132; 10\/73 patients (13.7%) experienced grade 3 treatment-related adverse events. Six patients discontinued because of adverse events, including two with events considered possibly related to treatment (including ongoing ICI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this single-arm phase 2a study, aglatimagene besadenovec plus valacyclovir with ongoing ICI was associated with systemic immune remodeling and encouraging survival. Because comparisons with historical controls are descriptive and vulnerable to selection and other biases, efficacy requires confirmation in a randomized controlled clinical trial, which has been initiated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04495153\">NCT04495153<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-015821","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:05:25Z","timestamp":1790615125000},"page":"e015821","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Prolonged survival after systemic immune reactivation by aglatimagene besadenovec plus valacyclovir in patients with unresectable stage III\/IV NSCLC with an inadequate response to ICI"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct04495153","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04495153","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Charu","family":"Aggarwal","sequence":"first","affiliation":[{"name":"University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sterman","sequence":"additional","affiliation":[{"name":"NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2185-0338","authenticated-orcid":false,"given":"Jessica","family":"Dwyer","sequence":"additional","affiliation":[{"name":"Candel Therapeutics Inc, Needham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin R","family":"Alesi","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University Massey Comprehensive Cancer Center, Richmond, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Maldonado","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranee","family":"Mehra","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bestvina","sequence":"additional","affiliation":[{"name":"The University of Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janani","family":"Reisenauer","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiven","family":"Patel","sequence":"additional","affiliation":[{"name":"University of Utah Health Huntsman Cancer Institute, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"UConn Health, Farmington, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Eapen","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Guesdon","sequence":"additional","affiliation":[{"name":"Sonrai Analytics, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3627-5669","authenticated-orcid":false,"given":"Matthew Wai Heng","family":"Chung","sequence":"additional","affiliation":[{"name":"Sonrai Analytics, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2742-1668","authenticated-orcid":false,"given":"Caroline","family":"Duault","sequence":"additional","affiliation":[{"name":"Institute for Immunity, Transplantation, Infections, Stanford University School of Medicine, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina Rohani","family":"Pichavant","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Gnjatic","sequence":"additional","affiliation":[{"name":"Medicine - Hem\/Onc, Icahn School of Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghee","family":"Kim-Schulze","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holden T","family":"Maecker","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0920-0549","authenticated-orcid":false,"given":"Anne R","family":"Diers","sequence":"additional","affiliation":[{"name":"Candel Therapeutics Inc, Needham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuchen","family":"Guo","sequence":"additional","affiliation":[{"name":"Candel Therapeutics Inc, Needham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett","family":"Nichols","sequence":"additional","affiliation":[{"name":"Candel Therapeutics Inc, Needham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Manzanera","sequence":"additional","affiliation":[{"name":"Candel Therapeutics Inc, Needham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Barone","sequence":"additional","affiliation":[{"name":"Candel Therapeutics Inc, Needham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul P","family":"Tak","sequence":"additional","affiliation":[{"name":"Candel Therapeutics Inc, Needham, Massachusetts, USA"},{"name":"Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"2026100605350887000_14.9.e015821.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"2026100605350887000_14.9.e015821.2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study","volume":"43","author":"Ahn","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026100605350887000_14.9.e015821.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00733"},{"key":"2026100605350887000_14.9.e015821.4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/08830185.2024.2401352","article-title":"The molecular landscape of T cell exhaustion in the tumor microenvironment and reinvigoration strategies","volume":"43","author":"Heidari-Foroozan","year":"2024","journal-title":"Int Rev Immunol"},{"key":"2026100605350887000_14.9.e015821.5","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1089\/hum.1996.7.4-515","article-title":"Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models","volume":"7","author":"Eastham","year":"1996","journal-title":"Hum Gene Ther"},{"key":"2026100605350887000_14.9.e015821.6","doi-asserted-by":"publisher","DOI":"10.1089\/10430340252792503"},{"key":"2026100605350887000_14.9.e015821.7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700281"},{"key":"2026100605350887000_14.9.e015821.8","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2011.56"},{"key":"2026100605350887000_14.9.e015821.9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1158\/2767-9764.CRC-24-0434","article-title":"Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy","volume":"5","author":"Diers","year":"2025","journal-title":"Cancer Res Commun"},{"key":"2026100605350887000_14.9.e015821.10","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19970117)70:2<183::AID-IJC8>3.0.CO;2-T"},{"key":"2026100605350887000_14.9.e015821.11","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2001.0298"},{"key":"2026100605350887000_14.9.e015821.12","first-page":"3221","article-title":"Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer","volume":"58","author":"Hall","year":"1998","journal-title":"Cancer Res"},{"key":"2026100605350887000_14.9.e015821.13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/neuonc\/nox139","article-title":"Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma","volume":"20","author":"Speranza","year":"2018","journal-title":"Neuro Oncol"},{"key":"2026100605350887000_14.9.e015821.14","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1470-2045(26)00071-9","article-title":"Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial","volume":"27","author":"DeWeese","year":"2026","journal-title":"Lancet Oncol"},{"key":"2026100605350887000_14.9.e015821.15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-SITC2023.0653"},{"key":"2026100605350887000_14.9.e015821.16","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-5-34"},{"key":"2026100605350887000_14.9.e015821.17","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ymthe.2020.11.001","article-title":"Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity","volume":"29","author":"Predina","year":"2021","journal-title":"Mol Ther"},{"key":"2026100605350887000_14.9.e015821.18","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1093\/neuonc\/noaf079","article-title":"A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma","volume":"27","author":"Wen","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026100605350887000_14.9.e015821.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2026100605350887000_14.9.e015821.20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003956","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma","volume":"10","author":"Govindan","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026100605350887000_14.9.e015821.21","doi-asserted-by":"crossref","DOI":"10.15252\/msb.20178124","article-title":"Multi-Omics Factor Analysis-a framework for unsupervised integration of multi-omics data sets","volume":"14","author":"Argelaguet","year":"2018","journal-title":"Mol Syst Biol"},{"key":"2026100605350887000_14.9.e015821.22","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-020-02015-1","article-title":"MOFA+: a statistical framework for comprehensive integration of multi-modal single-cell data","volume":"21","author":"Argelaguet","year":"2020","journal-title":"Genome Biol"},{"key":"2026100605350887000_14.9.e015821.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60845-X"},{"key":"2026100605350887000_14.9.e015821.24","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00912"},{"key":"2026100605350887000_14.9.e015821.25","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/1759-7714.13483","article-title":"Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review","volume":"11","author":"Kitagawa","year":"2020","journal-title":"Thorac Cancer"},{"key":"2026100605350887000_14.9.e015821.26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.9661"},{"key":"2026100605350887000_14.9.e015821.27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30624-6"},{"key":"2026100605350887000_14.9.e015821.28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad9784","article-title":"Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma","volume":"8","author":"Cloughesy","year":"2016","journal-title":"Sci Transl Med"},{"key":"2026100605350887000_14.9.e015821.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"2026100605350887000_14.9.e015821.30","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0175-2024","article-title":"The impact of smoking on lung cancer patients","volume":"34","author":"Minervini","year":"2025","journal-title":"Eur Respir Rev"},{"key":"2026100605350887000_14.9.e015821.31","doi-asserted-by":"crossref","first-page":"104307","DOI":"10.1016\/j.critrevonc.2024.104307","article-title":"Patients\u2019 selection and trial matching in early-phase oncology clinical trials","volume":"196","author":"Corbaux","year":"2024","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:35:22Z","timestamp":1791290122000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,28]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/jitc-2026-015821"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015821","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}